Anti-spike nanobody-IFN-β conjugated exosomes

An exosome-based anti-SARS-CoV-2 formulation.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Anti-spike nanobody-IFN-β conjugated exosomes are an COVID-19 formulation combining an anti-Spike (SARS-CoV-2) nanobody, interferon-β and an exosomal delivery platform (Lyu et al., 2022). Exosomes are a class of nano-sized cell-derived extracellular vesicles. They carry various types of natural or engineered cellular components or substances (Zhang et al., 2020). Interferon (IFN)-β is a polypeptide produced primarily by fibroblast. It has antiviral and antiproliferative properties facilitated by gene products whose transcription IFN-β regulates (Markowitz, 2007). Anti-spike nanobody-IFN-β conjugated exosomes were shown to inhibit SARS-CoV-2 pseudovirus infection and upregulate interferon-stimulated genes in vitro (Lyu et al., 2022).


Supporting references

Link Tested on Impact factor Notes Publication date
Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes
Spike protein Cell-based therapy Novel compound In vitro Mixed substance Extracellular vesicles
ACE2-expressing A549 cells; ACE2-expressing HEK-blue IFNα/β cells 4.20

The exosomal formulation displayed anti-SARS-CoV-2 activity in vitro.